AL-208

AL-208 is an investigational drug developed by Allon Therapeutics as an intravenous formulation of the neuroprotective peptide NAP (a fragment of activity-dependent neuroprotective protein). It is being studied primarily for the treatment of mild cognitive impairment following coronary artery bypass graft (CABG) surgery and other cognitive disorders. The drug has demonstrated safety and tolerability in Phase I clinical trials involving healthy and elderly adults, and has advanced to Phase II trials for cognitive disorder. Its mechanism involves neuroprotection, likely through stabilization of microtubules, similar to its related compound AL-108[1][2][3].